Skip to Content
Merck

Fire Up Your Research

Neuroinflammation Biomarker Immunoassays

Neuroimmunology & Neuroinflammation Immunoassays

The Role of Immunoassays in Neuroimmunology and Neuroinflammation Research

Neuroinflammation plays a key role in the chronic processes of neurodegenerative diseases resulting from traumatic brain injury (TBI) and spinal cord injury. Inflammation is associated with disease progression in Alzheimer’s disease (AD), Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Elevated pro-inflammatory markers in the aging brain can increase the risk for cognitive impairment and the development of neurodegenerative disease.

We offer MILLIPLEX® multiplex assays for the Luminex® instrument platform and high sensitivity Single Molecule Counting (SMC®) assays for the SMCxPRO® instrument platform to meet the needs of neuroscience researchers. These immunoassay tools enable scientists to explore neuroimmunology and neuroinflammation by monitoring biomarkers in advance of neurodegenerative disease onset, during chronic disease, and during potential therapeutic treatments to slow disease progression.

Concentrations of neuroinflammation cytokines IL-9, M-CSF, MDC, and IL-3 in CSF samples measured by MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A (Catalog number HCYTA-60K)

Figure 1.Concentration of MILLIPLEX® Human Panel A analytes in neurodegenerative disease samples. CSF samples were compared between healthy controls (n=9), mild cognitive impairment (MCI) samples (n=10), and AD samples (n=13). **p < 0.005 ***p > 0.0005.

Cytokine Analysis in Neurodegenerative Disease

Quantitating cytokine and chemokine markers of neuroinflammation and biomarkers of neurodegeneration in cerebral spinal fluid (CSF), serum/plasma, cell culture, and tissue lysate samples allow researchers to study disease progression associated with neuroinflammation and neurodegeneration. Neuroinflammation may play a role in AD and other neurodegenerative diseases, highlighting the utility of broadly profiling cytokines in CSF samples. The MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A and Panel B enable multiplexing of many types of bioassays reducing time, labor, and costs over traditional methods.

Concentrations of neurodegenerative disease biomarkers phosphorylated Tau (T181), total Tau, TDP-43, and SNAP-25 analyzed with ultrasensitive SMC® immunoassays.

Figure 2.CSF measurement of AD biomarkers. Analysis of control and AD CSF samples with each SMC® kit (SMC® Phospho-Tau (T181) Kit, SMC® Total Tau Kit, SMC® TDP-43 Kit, SMC® SNAP-25 Kit) revealed statistically significant differences in phosphorylated Tau T181 (p<0.02), total Tau (p<0.03), TDP-43 (p<0.01), and SNAP-25 (p<0.02).

Ultrasensitive Analysis of Neurodegenerative Disease Biomarkers

The need for blood-based biomarkers of AD has driven a continuous search for novel candidates. However, the identification of blood-based biomarkers may be limited by the sensitivity of standard immunoassay methodologies. High sensitivity immunoassay technologies, such as SMC® technology, can transform neurodegenerative disease research by enabling the measurement of low-abundant proteins in a variety of biofluids and create opportunities for the identification of novel biomarkers.


Request Info on Neuroinflammation Immunoassay Products


Related Ultrasensitive SMC® Assays
Loading

For Research Use Only. Not For Use In Diagnostic Procedures.

Related MILLIPLEX® Multiplex Assays
Loading

For Research Use Only. Not For Use In Diagnostic Procedures.

Related ELISAs
Loading

For Research Use Only. Not For Use In Diagnostic Procedures.


Related Product Resources

Page 1 of 3


Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?